Afterwards, in 2000, additional molecular correlates for CIMP-positive tumours were provided by Toyota et al. namely KRAS mutation enrichment and low TP53 mutation frequency when compared to CIMP-negative tumours [22]. This evidence concerns the gene KRAS and neoplasm.